{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:44:19Z","timestamp":1790869459030,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["PP00P3 170702"],"award-info":[{"award-number":["PP00P3 170702"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP 1032350"],"award-info":[{"award-number":["OPP 1032350"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parasite Epidemiology and Control"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.parepi.2020.e00145","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T23:18:33Z","timestamp":1588720713000},"page":"e00145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Future use-cases of vaccines in malaria control and elimination"],"prefix":"10.1016","volume":"10","author":[{"given":"Melissa A.","family":"Penny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Camponovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakul","family":"Chitnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parepi.2020.e00145_bb0005","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1056\/NEJMoa0807773","article-title":"Safety and immunogenicity of RTS,S\/AS02D malaria vaccine in infants","volume":"359","author":"Abdulla","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parepi.2020.e00145_bb0010","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1046\/j.1365-3156.1999.00406.x","article-title":"Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania","volume":"4","author":"Acosta","year":"1999","journal-title":"Tropical Med. Int. Health"},{"issue":"5","key":"10.1016\/j.parepi.2020.e00145_bb0015","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1046\/j.1365-3156.1999.00406.x","article-title":"Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania","volume":"4","author":"Acosta","year":"1999","journal-title":"Tropical Med. Int. Health"},{"key":"10.1016\/j.parepi.2020.e00145_bb0020","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"Agnandji","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parepi.2020.e00145_bb0025","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants","volume":"367","author":"Agnandji","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.parepi.2020.e00145_bb0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0025-5564(94)90025-6","article-title":"Some discrete-time SI, SIR, and SIS epidemic models","volume":"124","author":"Allen","year":"1994","journal-title":"Math. Biosci."},{"key":"10.1016\/j.parepi.2020.e00145_bb0035","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(94)90505-3","article-title":"Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania","volume":"344","author":"Alonso","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.parepi.2020.e00145_bb0040","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S0140-6736(04)17223-1","article-title":"Efficacy of the RTS,S\/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial","volume":"364","author":"Alonso","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.parepi.2020.e00145_bb0045","series-title":"Naval Medical Research INST Bethesda MD","article-title":"Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine","author":"Ballou","year":"1987"},{"issue":"474","key":"10.1016\/j.parepi.2020.e00145_bb0050","doi-asserted-by":"crossref","first-page":"eaau1458","DOI":"10.1126\/scitranslmed.aau1458","article-title":"Challenges and strategies for developing efficacious and long-lasting malaria vaccines","volume":"11","author":"Beeson","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.parepi.2020.e00145_bb0055","first-page":"S84","article-title":"Safety, immunogenicity and efficacy studies of candidate malaria vaccines FP9 and MVA encoding ME-TRAP in Kenyan children [MIM-PB-224908]","volume":"95","author":"Bejon","year":"2005","journal-title":"Acta Trop."},{"issue":"7572","key":"10.1016\/j.parepi.2020.e00145_bb0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nature15535","article-title":"The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015","volume":"526","author":"Bhatt","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.parepi.2020.e00145_bb0065","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(01)06957-4","article-title":"Efficacy of RTS,S\/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial","volume":"358","author":"Bojang","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.parepi.2020.e00145_bb0070","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4161\/hv.5.4.7050","article-title":"Five-year safety and immunogenicity of Glaxo Smith Kline\u2019s candidate malaria vaccine RTS,S\/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia","volume":"5","author":"Bojang","year":"2009","journal-title":"Hum. Vaccin. Immunother."},{"issue":"7","key":"10.1016\/j.parepi.2020.e00145_bb0075","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1016\/S2214-109X(17)30220-6","article-title":"Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study","volume":"5","author":"Brady","year":"2017","journal-title":"Lancet Glob. Health"},{"issue":"10180","key":"10.1016\/j.parepi.2020.e00145_bb0080","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0140-6736(18)32613-8","article-title":"Advancing the repurposing of ivermectin for malaria","volume":"393","author":"Chaccour","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.parepi.2020.e00145_bb0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1475-2875-11-122","article-title":"Malaria resurgence: a systematic review and assessment of its causes","volume":"11","author":"Cohen","year":"2012","journal-title":"Malar. J."},{"key":"10.1016\/j.parepi.2020.e00145_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/srep46621","article-title":"Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine","volume":"7","author":"Collins","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.parepi.2020.e00145_bb0095","series-title":"Mathematical Models for Transmission and Control of Malaria","first-page":"1091","author":"Dietz","year":"1988"},{"key":"10.1016\/j.parepi.2020.e00145_bb0100","first-page":"109","article-title":"DNA vaccines for malaria: the past, the present, & the future","volume":"106","author":"Doolan","year":"1997","journal-title":"Indian J. Med. Res."},{"issue":"1","key":"10.1016\/j.parepi.2020.e00145_bb0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.chom.2018.06.008","article-title":"Malaria vaccines: recent advances and new horizons","volume":"24","author":"Draper","year":"2018","journal-title":"Cell Host Microbe"},{"issue":"21","key":"10.1016\/j.parepi.2020.e00145_bb0110","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1242\/jeb.00642","article-title":"Prime-boost strategies for malaria vaccine development","volume":"206","author":"Dunachie","year":"2003","journal-title":"J. Exp. Biol."},{"issue":"13","key":"10.1016\/j.parepi.2020.e00145_bb0115","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1089\/10430340260201644","article-title":"Safety, tolerability, and lack of antibody responses after administration of a Pf CSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular\/intradermal routes","volume":"13","author":"Epstein","year":"2002","journal-title":"Hum. Gene Ther."},{"issue":"5","key":"10.1016\/j.parepi.2020.e00145_bb0120","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/QCO.0b013e3282dd7a29","article-title":"Asexual blood-stage malaria vaccine development: facing the challenges","volume":"20","author":"Genton","year":"2007","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.parepi.2020.e00145_bb0125","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1086\/339342","article-title":"A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea","volume":"185","author":"Genton","year":"2002","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.parepi.2020.e00145_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001994","article-title":"The future of the RTS, S\/AS01 malaria vaccine: an alternative development plan","volume":"13","author":"Gosling","year":"2016","journal-title":"PLoS Med."},{"issue":"1","key":"10.1016\/j.parepi.2020.e00145_bb0135","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12936-017-1841-9","article-title":"Seasonal vaccination against malaria: a potential use for an imperfect malaria vaccine","volume":"16","author":"Greenwood","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.parepi.2020.e00145_bb0140","doi-asserted-by":"crossref","first-page":"a025627","DOI":"10.1101\/cshperspect.a025627","article-title":"Vaccines to accelerate malaria elimination and eventual eradication","author":"Healer","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"529","key":"10.1016\/j.parepi.2020.e00145_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw9522","article-title":"Immune system development varies according to age, location, and anemia in African children","volume":"12","author":"Hill","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.parepi.2020.e00145_bb0150","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1126\/science.3299709","article-title":"Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications","volume":"237","author":"Hoffman","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.parepi.2020.e00145_bb0155","doi-asserted-by":"crossref","first-page":"D13","DOI":"10.1016\/j.vaccine.2015.07.091","article-title":"The march toward malaria vaccines","volume":"33","author":"Hoffman","year":"2015","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.parepi.2020.e00145_bb0165","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.4512","article-title":"A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite","volume":"24","author":"Kisalu","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.parepi.2020.e00145_bb0170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12916-019-1277-x","article-title":"Induction and decay of functional complement-fixing antibodies by the RTS, S malaria vaccine in children, and a negative impact of malaria exposure","volume":"17","author":"Kurtovic","year":"2019","journal-title":"BMC Med."},{"issue":"5580","key":"10.1016\/j.parepi.2020.e00145_bb0175","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1126\/science.1074484","article-title":"Malaria-from infants to genomics to vaccines","volume":"297","author":"Long","year":"2002","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.parepi.2020.e00145_bb0180","doi-asserted-by":"crossref","first-page":"e1002455","DOI":"10.1371\/journal.pmed.1002455","article-title":"malERA: an updated research agenda for diagnostics, drugs, vaccines, and vector control in malaria elimination and eradication","volume":"14","author":"malERA Refresh Consultative Panel on Tools for Malaria Elimination","year":"2017","journal-title":"PLoS Med."},{"issue":"25","key":"10.1016\/j.parepi.2020.e00145_bb0185","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1056\/NEJMoa1513137","article-title":"A worldwide map of Plasmodium falciparum K13-propeller polymorphisms","volume":"374","author":"M\u00e9nard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parepi.2020.e00145_bb0190","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cois.2019.12.001","article-title":"Effects of insecticide resistance and exposure on Plasmodium development in Anopheles mosquitoes","volume":"39","author":"Minetti","year":"2020","journal-title":"Curr. Opin. Insect Sci."},{"issue":"6","key":"10.1016\/j.parepi.2020.e00145_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002047","article-title":"Age, spatial, and temporal variations in hospital admissions with malaria in Kilifi County, Kenya: a 25-year longitudinal observational study","volume":"13","author":"Mogeni","year":"2016","journal-title":"PLoS Med."},{"issue":"9906","key":"10.1016\/j.parepi.2020.e00145_bb0200","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(13)62238-2","article-title":"Malaria vaccine technology roadmap","volume":"382","author":"Moorthy","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.parepi.2020.e00145_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41597-019-0134-2","article-title":"Analysis-ready datasets for insecticide resistance phenotype and genotype frequency in African malaria vectors","volume":"6","author":"Moyes","year":"2019","journal-title":"Sci. Data"},{"issue":"2","key":"10.1016\/j.parepi.2020.e00145_bb0210","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.pt.2016.11.006","article-title":"Changes in malaria epidemiology in Africa and new challenges for elimination","volume":"33","author":"Nkumama","year":"2017","journal-title":"Trends Parasitol."},{"issue":"9029","key":"10.1016\/j.parepi.2020.e00145_bb0215","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0140-6736(96)04465-0","article-title":"Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand","volume":"348","author":"Nosten","year":"1996","journal-title":"Lancet"},{"issue":"1131","key":"10.1016\/j.parepi.2020.e00145_bb0220","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1098\/rstb.1984.0113","article-title":"Development of sporozoite vaccines","volume":"307","author":"Nussenzweig","year":"1984","journal-title":"Phil. Trans. R Soc. Lond. B"},{"issue":"5111","key":"10.1016\/j.parepi.2020.e00145_bb0225","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/216160a0","article-title":"Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei","volume":"216","author":"Nussenzweig","year":"1967","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.parepi.2020.e00145_bb0230","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4269\/ajtmh.17-0449","article-title":"Advancing global health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of PfSPZ vaccine for malaria in healthy Equatoguinean men","volume":"98","author":"Olotu","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"13","key":"10.1016\/j.parepi.2020.e00145_bb0235","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/sj.gt.3301491","article-title":"Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine","volume":"8","author":"Parker","year":"2001","journal-title":"Gene Ther."},{"issue":"9","key":"10.1016\/j.parepi.2020.e00145_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003193","article-title":"What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines","volume":"3","author":"Penny","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.parepi.2020.e00145_bb0245","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s12936-015-0969-8","article-title":"The time-course of protection of the RTS,S vaccine against malaria infections and clinical malaria","volume":"14","author":"Penny","year":"2015","journal-title":"Malar. J."},{"issue":"10016","key":"10.1016\/j.parepi.2020.e00145_bb0250","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0140-6736(15)00725-4","article-title":"Public health impact and cost-effectiveness of the RTS,S\/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models","volume":"387","author":"Penny","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.parepi.2020.e00145_bb0255","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1126\/science.318.5856.1544","article-title":"Malaria. Did they really say \u2026 eradication?","volume":"318","author":"Roberts","year":"2007","journal-title":"Science"},{"issue":"9988","key":"10.1016\/j.parepi.2020.e00145_bb0260","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"RTSS Clinical Trials Partnership","year":"2015","journal-title":"Lancet"},{"issue":"23\u201324","key":"10.1016\/j.parepi.2020.e00145_bb0265","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1016\/S0264-410X(99)00175-9","article-title":"Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant","volume":"17","author":"Saul","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.parepi.2020.e00145_bb0270","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.35213","article-title":"Synergy in anti-malarial pre-erythrocytic and transmission-blocking antibodies is achieved by reducing parasite density","volume":"7","author":"Sherrard-Smith","year":"2018","journal-title":"eLife"},{"issue":"6","key":"10.1016\/j.parepi.2020.e00145_bb0275","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(18)30163-4","article-title":"Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial","volume":"18","author":"Smit","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.parepi.2020.e00145_bb0280","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1017\/S0031182008000371","article-title":"Towards a comprehensive simulation model of malaria epidemiology and control","volume":"135","author":"Smith","year":"2008","journal-title":"Parasitology"},{"issue":"5","key":"10.1016\/j.parepi.2020.e00145_bb0285","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pt.2010.12.011","article-title":"Uses of mosquito-stage transmission-blocking vaccines against Plasmodium falciparum","volume":"27","author":"Smith","year":"2011","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.parepi.2020.e00145_bb0290","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199701093360202","article-title":"A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group","volume":"336","author":"Stoute","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.parepi.2020.e00145_bb0295","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4269\/ajtmh.1995.53.423","article-title":"Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults","volume":"53","author":"Stuerchler","year":"1995","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"4","key":"10.1016\/j.parepi.2020.e00145_bb0300","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm.4513","article-title":"A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein","volume":"24","author":"Tan","year":"2018","journal-title":"Nat. Med."},{"issue":"127","key":"10.1016\/j.parepi.2020.e00145_bb0305","first-page":"1186","article-title":"Simulation of the cost-effectiveness of malaria vaccines","volume":"8","author":"Tediosi","year":"2009","journal-title":"Malar. J."},{"issue":"1","key":"10.1016\/j.parepi.2020.e00145_bb0310","doi-asserted-by":"crossref","first-page":"e1000398","DOI":"10.1371\/journal.pmed.1000398","article-title":"A research agenda for malaria eradication: vaccines","volume":"8","author":"The malERA Consultative Group on Vaccines","year":"2011","journal-title":"PLoS Med."},{"issue":"16","key":"10.1016\/j.parepi.2020.e00145_bb0315","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1111\/febs.14127","article-title":"Combating multidrug-resistant Plasmodium falciparum malaria","volume":"284","author":"Thu","year":"2017","journal-title":"FEBS J."},{"issue":"12","key":"10.1016\/j.parepi.2020.e00145_bb0320","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS,S\/AS01 malaria vaccine over time and implications for duration of vaccine efficacy: analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.parepi.2020.e00145_bb0325","series-title":"WHO Preferred Product Characteristics for Malaria Vaccines","author":"World Health Organisation","year":"2015"},{"key":"10.1016\/j.parepi.2020.e00145_bb0330","series-title":"Presented at. In: International Conference on Primary Health Care Alma Ata: 1978","article-title":"The declaration of Alma Ata","author":"World Health Organization","year":"1978"},{"issue":"91","key":"10.1016\/j.parepi.2020.e00145_bb0335","first-page":"33","article-title":"Malaria vaccine: WHO position paper \u2013 January 2016","volume":"4","author":"World Health Organization","year":"2016","journal-title":"WHO Wkly. Epidemiol. Rec."},{"key":"10.1016\/j.parepi.2020.e00145_bb0340","series-title":"World Malaria Report 2017","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.parepi.2020.e00145_bb0345","unstructured":"World Health Organization: Meeting of the global advisory committee on vaccine safety, 7\u20138 June 2017. Wkly Epidemiol. Rec. 2017, 28(92):393\u2013404."}],"container-title":["Parasite Epidemiology and Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405673120300143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405673120300143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:50:45Z","timestamp":1778881845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405673120300143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":68,"alternative-id":["S2405673120300143"],"URL":"https:\/\/doi.org\/10.1016\/j.parepi.2020.e00145","relation":{},"ISSN":["2405-6731"],"issn-type":[{"value":"2405-6731","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future use-cases of vaccines in malaria control and elimination","name":"articletitle","label":"Article Title"},{"value":"Parasite Epidemiology and Control","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parepi.2020.e00145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of World Federation of Parasitologists.","name":"copyright","label":"Copyright"}],"article-number":"e00145"}}